149 related articles for article (PubMed ID: 7742042)
21. IgA immunity in HIV type 1-infected chimpanzees. I. Systemic immunity.
Black KP; Fultz PN; Girard M; Jackson S
AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1263-72. PubMed ID: 9339843
[TBL] [Abstract][Full Text] [Related]
22. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
[TBL] [Abstract][Full Text] [Related]
23. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
[TBL] [Abstract][Full Text] [Related]
24. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
[TBL] [Abstract][Full Text] [Related]
25. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
Thakar MR; Bhonge LS; Lakhashe SK; Shankarkumar U; Sane SS; Kulkarni SS; Mahajan BA; Paranjape RS
J Infect Dis; 2005 Sep; 192(5):749-59. PubMed ID: 16088824
[TBL] [Abstract][Full Text] [Related]
26. Correlation of maternal cytophilic human immunodeficiency virus (HIV)-1 V3 loop peptide-specific antibodies in infants with vertical HIV transmission.
Wang XP; Oyaizu N; Pahwa S
Pediatr Res; 1995 Sep; 38(3):384-9. PubMed ID: 7494664
[TBL] [Abstract][Full Text] [Related]
27. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
28. Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge.
Buge SL; Ma HL; Amara RR; Wyatt LS; Earl PL; Villinger F; Montefiori DC; Staprans SI; Xu Y; Carter E; O'Neil SP; Herndon JG; Hill E; Moss B; Robinson HL; McNicholl JM
AIDS Res Hum Retroviruses; 2003 Oct; 19(10):891-900. PubMed ID: 14585221
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 infection in pigtailed macaques.
Gartner S; Liu Y; Lewis MG; Polonis V; Elkins WR; Zack PM; Miao J; Hunter EA; Greenhouse J; Eddy GA
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S129-33. PubMed ID: 7865287
[TBL] [Abstract][Full Text] [Related]
30. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA.
Lockridge KM; Chien M; Dean GA; Stefano Cole K; Montelaro RC; Luciw PA; Sparger EE
Virology; 2000 Jul; 273(1):67-79. PubMed ID: 10891409
[TBL] [Abstract][Full Text] [Related]
31. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
McBurney SP; Young KR; Ross TM
Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal study of humoral immune responses in HIV type 1 subtype CRF01_AE (E)-infected Thai patients with different rates of disease progression.
Chuenchitra T; Wasi C; Louisirirojchanakul S; Nitayaphan S; Sutthent R; Cox JH; De Souza MS; Brown AE; Birx DL; Polonis VR
AIDS Res Hum Retroviruses; 2003 Apr; 19(4):293-305. PubMed ID: 12804005
[TBL] [Abstract][Full Text] [Related]
33. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.
Pincus SH; Messer KG; Nara PL; Blattner WA; Colclough G; Reitz M
J Clin Invest; 1994 Jun; 93(6):2505-13. PubMed ID: 7515393
[TBL] [Abstract][Full Text] [Related]
34. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
[TBL] [Abstract][Full Text] [Related]
35. Identification and characterization of HLA-A*3303-restricted, HIV type 1 Pol- and Gag-derived cytotoxic T cell epitopes.
Hossain MS; Tomiyama H; Inagawa T; Ida S; Oka S; Takiguchi M
AIDS Res Hum Retroviruses; 2003 Jun; 19(6):503-10. PubMed ID: 12882660
[TBL] [Abstract][Full Text] [Related]
36. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
37. Infection of baboons with simian/human immunodeficiency viruses.
Allan JS; Ray P; Broussard S; Whitehead E; Hubbard G; Butler T; Brasky K; Luciw P; Cheng-Mayer C; Levy JA
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Aug; 9(5):429-41. PubMed ID: 7627620
[TBL] [Abstract][Full Text] [Related]
38. Persistent infection with SIVmac chimeric virus having tat, rev, vpu, env and nef of HIV type 1 in macaque monkeys.
Igarashi T; Shibata R; Hasebe F; Ami Y; Shinohara K; Komatsu T; Stahl-Hennig C; Petry H; Hunsmann G; Kuwata T
AIDS Res Hum Retroviruses; 1994 Aug; 10(8):1021-9. PubMed ID: 7811533
[TBL] [Abstract][Full Text] [Related]
39. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection.
Huber M; Fischer M; Misselwitz B; Manrique A; Kuster H; Niederöst B; Weber R; von Wyl V; Günthard HF; Trkola A
PLoS Med; 2006 Nov; 3(11):e441. PubMed ID: 17121450
[TBL] [Abstract][Full Text] [Related]
40. Detection and differentiation of HIV-1 group O sera from HIV-1 group M and HIV-2 using recombinant antigens and peptides.
Hickman RK; Vallari A; Golden A; Lund J; Hackett J; Brennan C; Devare S
J Virol Methods; 1998 May; 72(1):43-9. PubMed ID: 9672131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
